CASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting

Interim Results:

CID-103 demonstrated a manageable safety profile with only two Grade 3 treatment-related events and no dose limiting toxicities observed

All infusion-related reactions (IRR) occurred with priming dose and are due to low grade AEs

Primary Efficacy Endpoint achieved in 8 of 11 (73%) patients

6 of 8 (75%) patients achieved Complete Response (CR) with platelet improvement observed as early as one week post dose

Reduction of PD markers (decreased anti-platelet antibodies, immunoglobulins, NK and plasma cells) is consistent with the presumed CID-103 MOA resulting in the observed platelet response